Key Highlights
- FirstLight and RadiantLight Phase 3 studies met all primary and secondary endpoints with highly significant results (p<0.001) across key measures including wakefulness, cataplexy, symptom severity, and quality of life.
- Oveporexton, a potential first-in-class oral orexin receptor 2 agonist, showed a favorable safety profile consistent with earlier studies.
- Takeda plans global regulatory submissions starting in FY2025, positioning oveporexton as the first therapy to directly address the underlying cause of narcolepsy type 1 (NT1).
Clinical Breakthroughs Across Endpoints
Patients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most achieving normative ranges on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS). Weekly cataplexy rates were reduced by over 80%, with patients gaining a median of 4–5 cataplexy-free days per week. Over 70% reported mild or minimal disease severity, while quality-of-life measures such as SF-36 and EQ-5D-5L approached scores seen in healthy populations.
Safety and Tolerability
No treatment-related serious adverse events were reported. The most common adverse events were mild to moderate and included insomnia, urinary urgency, and frequency, aligning with prior trial findings.
A New Era in Orexin Science
Takeda leads the global effort in orexin research with a diversified franchise of assets spanning narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, and other orexin-related disorders. With oveporexton as the lead candidate, Takeda is advancing a potentially transformative therapy class in sleep medicine and neuroscience.
About Takeda
Takeda (TSE: 4502/NYSE: TAK) is a values-based, R&D-driven global biopharmaceutical leader headquartered in Japan, with operations in ~80 countries. Focused on creating better health for people and a brighter future for the world, Takeda advances innovative medicines in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. With over two centuries of heritage, Takeda is committed to improving patient outcomes and delivering long-term value for society and investors.
By